Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation.

导出 OA

翻译打印收藏纠错

作者： Yunju,Nam ^[1] ; Injae,Shin ^[1] ; Younghoon,Kim ^[1] ; SeongShick,Ryu ^[1] ; Namdoo,Kim ^[2] ; Eunhye,Ju ^[3] ; Taebo,Sim ^[4]

作者单位： KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea; Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea. ^[1] Voronoibio Inc., 32 Songdogwahak-ro, Yeonsu-gu, Incheon, 21984, Republic of Korea. ^[2] KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea. ^[3] KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea; Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea. Electronic address: tbsim@yuhs.ac. ^[4]

关键词 FGFR4 inhibitor FGFR4 kinase GNF-7 HCC SAR